Pfizer (PFE) reported Q2 FY 2018 earnings of $0.81 per share (versus $0.67 in Q2 FY 2017), beating analysts' consensus estimate of $0.74.

The company's quarterly revenues amounted to $13.466 bln (+4.4% y/y), beating analysts' consensus estimate of $13.298 bln.

The company also issued guidance for FY 2018, projecting EPS of $2.95-3.05 (compared to its prior guidance of $2.90-3.00 and analysts' consensus estimate of $2.95) and revenues of $53-55 bln (compared to its prior guidance of $53.5-55.5 bln and analysts' consensus estimate of $54.25 bln).

PFE fell to $38.50 (-0.23%) in pre-market trading.